Vivek Narayan, MD
Medical Oncology · Philadelphia, PANPI 1346568011
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $87,948 of the $115,923 with a category attached, or 75.9%. It is spread thinly across 23 manufacturers, the largest accounting for just 10.8%. Among medical oncology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 128 payments — averaging $905.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$12K
- Sanofi$12K
- Exelixis Inc.$11K
- AstraZeneca$10K
- Sumitomo Pharma America, Inc.$9K
- EMD Serono, Inc.$8K
- plus $53K from 17 others
Across 262 payments — averaging $40,144 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$8.5M
- Pfizer$724K
- E.r. Squibb & Sons, L.L.C.$336K
- Janssen Research & Development, LLC$314K
- Regeneron$221K
- Bristol Myers Squibb$220K
- plus $233K from 3 others
What the payments were for
- Consulting fees$87,94876%
- Speaking & faculty fees$15,75014%
- Travel & lodging$7,7227%
- Food & beverage$4,4764%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 10 | $12,469 |
| Sanofi | 14 | $12,221 |
| Exelixis Inc. | 25 | $11,327 |
| AstraZeneca | 16 | $9,607 |
| Sumitomo Pharma America, Inc. | 4 | $9,345 |
| EMD Serono, Inc. | 8 | $7,799 |
| Regeneron | 7 | $6,752 |
| Astellas Pharma US Inc | 5 | $5,867 |
| Eisai Inc. | 7 | $5,433 |
| Taiho Oncology, Inc. | 4 | $4,991 |
| Merck | 6 | $4,595 |
| Janssen Scientific Affairs, LLC | 5 | $4,251 |
| Johnson & Johnson(2 entities) | 4 | $4,163 |
| E.r. Squibb & Sons, L.L.C. | 1 | $3,600 |
| Bayer | 1 | $3,456 |
| Astrazeneca UK Limited | 1 | $2,740 |
| AVEO Pharmaceuticals, Inc. | 1 | $2,100 |
| Astellas Pharma Global Development | 1 | $2,100 |
| Amgen | 1 | $1,947 |
| Janssen Research & Development, LLC | 3 | $984 |
| Myovant Sciences Inc. | 2 | $97 |
| Seagen Inc. | 1 | $60 |
| Caris MPI, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$115,923 in reported general payments places this provider in the 90th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 108 | $1,407,247 |
| CabometyxCabozantinib S-Malate | 39 | $970,850 |
| LenvimaLenvatinib Mesylate | 27 | $621,293 |
| WeliregBelzutifan | 15 | $425,801 |
| NubeqaDarolutamide | 23 | $303,732 |
| InlytaAxitinib | 15 | $277,317 |
| Abiraterone Acetate | 45 | $139,512 |
| OrgovyxRelugolix | 16 | $38,636 |
| Prednisone | 49 | $329 |
| Bicalutamide | 26 | $323 |
| Levothyroxine Sodium | 15 | $38 |
| Klor-Con M20Potassium Chloride | 11 | $7 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $5,867 | $1,407,247108 claims |
| Exelixis Inc.Cabometyx | $11,327 | $970,85039 claims |
| Eisai Inc.Lenvima | $5,433 | $621,29327 claims |
| MerckWelireg | $4,595 | $425,80115 claims |
| BayerNubeqa | $3,456 | $303,73223 claims |
| PfizerInlyta | $12,469 | $277,31715 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $4,251 | $139,51245 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $9,345 | $38,63616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 238 medical oncology providers in Pennsylvania.
Other medical oncology in Philadelphia
- Carl JunePhiladelphia$9M
- Shayma KazmiPhiladelphia$619K
- Marcia BrosePhiladelphia$260K
- Adam CohenPhiladelphia$239K
- Daniel HallerPhiladelphia$227K
- Edith MitchellPhiladelphia$220K
- Elizabeth PlimackPhiladelphia$190K
- Alexander PerlPhiladelphia$176K
- Martin EdelmanPhiladelphia$157K
- Jean-Pierre IssaPhiladelphia$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.